FG-3019: Phase 1 Trial for IPF

1
FG-3019 Phase 1 Trial for IPF

• Human monoclonal antibody against connective
  tissue growth factor (CTGF), a growth factor that
  plays a key role in fibrosis
• Reduces scarring and excess deposition of ECM in
  preclinical models
• Phase 1 trial of FG-3019
• Evaluated safety, pharmacokinetics,
  immunogenicity in patients with IPF
• Patients treated with FG-3019 at 1, 3, or 10
  mg/kg by IV infusion for 2 hours
• FG-3019 was safe and well tolerated
• Phase 2 trial planned for 2005

Coalition for Pulmonary Fibrosis. ACT.
October-December 2004. Mageto Y, et al. CHEST.
October 26, 2004 Seattle, WA.